ORGANOVO, INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$430K

Filings

Firms Hired

Active Period

2015–2017

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2017	$230,000	4	1
2016	$200,000	6	2
2015	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ORGANOVO, INC.	$430,000	9
THE CONAFAY GROUP, LLC	—	6

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	13
SENATE	13
Food & Drug Administration (FDA)	8
Health & Human Services, Dept of (HHS)	8

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	15
Budget/Appropriations	Budget/Appropriations	9
Environment/Superfund	Environment/Superfund	3

Bills Explicitly Cited (20)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6463114th Congress

Patient Safety and Toxicology Modernization Act of 2016

2016 · fourth_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act Issues related to H.R. 6463 Patient Safety Toxicology Modernization Act

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 6463

S. 185114th Congress

PATH Act

2016 · fourth_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act Issues related to H.R. 6463 Patient Safety Toxicology Modernization Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 185

S. 2689114th Congress

REGROW Act

2016 · fourth_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act Issues related to H.R. 6463 Patient Safety Toxicology Modernization Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 2689

S. 679114th Congress

Quality Data, Quality Healthcare Act of 2015

2016 · fourth_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S.679, Toxic Substances Control Act (TSCA).

Client expense: $50,000 · Firm income: —

Matched citations: S.679

Show 16 more cited filings

S. 185114th Congress

PATH Act

2016 · third_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 185

S. 2689114th Congress

REGROW Act

2016 · third_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 2689

S. 679114th Congress

Quality Data, Quality Healthcare Act of 2015

2016 · third_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S.679, Toxic Substances Control Act (TSCA).

Client expense: $50,000 · Firm income: —

Matched citations: S.679

S. 185114th Congress

PATH Act

2016 · second_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 185

S. 2689114th Congress

REGROW Act

2016 · second_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 2689

S. 679114th Congress

Quality Data, Quality Healthcare Act of 2015

2016 · second_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S.679, Toxic Substances Control Act (TSCA).

Client expense: $50,000 · Firm income: —

Matched citations: S.679

S. 185114th Congress

PATH Act

2016 · first_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 185

S. 2689114th Congress

REGROW Act

2016 · first_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to S. 2689 Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act Issues related to S. 185 Promise for Antibiotics and Therapeutics for Health (PATH) Act

Client expense: $50,000 · Firm income: —

Matched citations: S. 2689

S. 185114th Congress

PATH Act

2016 · first_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the "21st Century Cures" agenda, including: S.2689, the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) act; and S. 185, Promise for Antibiotics and Therapeutics for Health (PATH) Act; Issues related to the FY'17 Labor, HHS and Agriculture Appropriations funding legislation

Client expense: — · Firm income: —

Matched citations: S. 185

S. 185114th Congress

PATH Act

2016 · first_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the "21st Century Cures" agenda, including: S.2689, the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) act; and S. 185, Promise for Antibiotics and Therapeutics for Health (PATH) Act; Issues related to the FY'17 Labor, HHS and Agriculture Appropriations funding legislation

Client expense: — · Firm income: —

Matched citations: S. 185

S. 2689114th Congress

REGROW Act

2016 · first_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the "21st Century Cures" agenda, including: S.2689, the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) act; and S. 185, Promise for Antibiotics and Therapeutics for Health (PATH) Act; Issues related to the FY'17 Labor, HHS and Agriculture Appropriations funding legislation

Client expense: — · Firm income: —

Matched citations: S.2689

S. 2689114th Congress

REGROW Act

2016 · first_quarter · Firm: ORGANOVO, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the "21st Century Cures" agenda, including: S.2689, the Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) act; and S. 185, Promise for Antibiotics and Therapeutics for Health (PATH) Act; Issues related to the FY'17 Labor, HHS and Agriculture Appropriations funding legislation

Client expense: — · Firm income: —

Matched citations: S.2689

H.R. 6114th Congress

21st Century Cures Act

2016 · first_quarter · Firm: THE CONAFAY GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2015 · fourth_quarter · Firm: THE CONAFAY GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2015 · third_quarter · Firm: THE CONAFAY GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications

Client expense: — · Firm income: $20,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2015 · second_quarter · Firm: THE CONAFAY GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications

Client expense: — · Firm income: $10,000

Matched citations: H.R. 6

Source: Senate LDA

ORGANOVO, INC. — Lobbying Disclosure | Poliscope